At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Rituximab, and 4 other interventions for Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue and 8 related conditions. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
This phase II trial is studying how well giving rituximab and cyclophosphamide together with bortezomib and dexamethasone (R-CyBor-D) works in treating patients with relapsed or refractory low-grade follicular lymphoma, Waldenstrom macroglobulinemia, or mantle cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab and bortezomib together with combination chemotherapy may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given PO
Given PO
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)